Pharmacologic Treatment of Sex Offenders With Paraphilic Disorder

  • Frederico Duarte Garcia
  • Heloise Garcia Delavenne
  • Alessandra de Fátima Almeida Assumpção
  • Florence Thibaut
Sexual Disorders (JP Fedoroff, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sexual Disorders

Abstract

Sexual offending is both a social and a public health issue. Evidence demonstrates that a combination of pharmacological and psychotherapeutic approaches may reduce or even eliminate deviant sexual behavior in sex offenders with paraphilic disorders. In this article, we will review pharmacological treatment options for sex offenders with paraphilias. Both serotonin selective reuptake inhibitors (SSRIs) and antiandrogen treatments have been used with reported success in decreasing recidivism. SSRIs have been used in mild types of paraphilias and juvenile paraphilias. Antiandrogen treatments seem to be effective in severe sex offenders with paraphilic disorders in order to reduce victimization. Combined pharmacological and psychotherapeutic treatment is associated with better efficacy. Imaging studies may improve the knowledge of paraphilic disorders and the mechanisms of action of current treatments. In spite of existing evidence, there is a need for independent, large-scale and good quality studies assessing the long-term efficacy and tolerance of treatments.

Keywords

Sex Offender Paraphilia Pedophilia Pharmacologic Treatment Selective Serotonin Reuptake Inhibitor SSRI Androgen Deprivation Therapy Steroidal Antiandrogen Treatments Medroxyprogesterone Acetate MPA Cyproterone Acetate CPA Gonadotropin-Releasing Hormone Analog GnRHa Goserelin Leuprorelin Triptorelin Sexual Disorders Psychiatry 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Post L, Mezey N, Maxwell N, Wilbert W. The rape tax: tangible and intangible costs of sexual violence. J Interpers Violence. 2002;17(7):773–82.CrossRefGoogle Scholar
  2. 2.
    Birger M, Bergman-Levy T, Asman O. Treatment of sex offenders in Israeli prison settings. J Am Acad Psychiatry Law. 2011;39(1):100–3.PubMedGoogle Scholar
  3. 3.
    Total sexual violence at the national level, number of police-recorded offences [database on the Internet]. United Nations Office on Drugs and Crime. 2012. Available from: http://www.unodc.org/documents/data-and-analysis/statistics/crime/CTS12_Sexual_violence.xls. Accessed 25 Dec 2012.
  4. 4.
    Garcia FD, Thibaut F. Sexual addictions. Am J Drug Alcohol Abuse. 2010;36(5):254–60. doi:10.3109/00952990.2010.503823.PubMedCrossRefGoogle Scholar
  5. 5.
    •• Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. Drugs. 2011;71(6):771–90. doi:10.2165/11585490-000000000-00000. This paper, which complements Thibaut et al. [6], critically reviews the current literature concerning selective serotonin reuptake inhibitors (SSRI).PubMedCrossRefGoogle Scholar
  6. 6.
    •• Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry. 2010;11(4):604–55. doi:10.3109/15622971003671628. These guidelines review and critically analyze the available literature about paraphilia treatment.PubMedCrossRefGoogle Scholar
  7. 7.
    Craig LA, Browne KD, Stringer I, Hogue TE. Sexual reconviction rates in the United Kingdom and actuarial risk estimates. Child Abuse Negl. 2008;32(1):121–38. doi:10.1016/j.chiabu.2007.09.002.PubMedCrossRefGoogle Scholar
  8. 8.
    Hanson RK, Morton KE, Harris AJ. Sexual offender recidivism risk: what we know and what we need to know. Ann N Y Acad Sci. 2003;989:154–66. discussion 236-46.PubMedCrossRefGoogle Scholar
  9. 9.
    Hanson RK, Morton-Bourgon KE. The characteristics of persistent sexual offenders: a meta-analysis of recidivism studies. J Consult Clin Psychol. 2005;73(6):1154–63. doi:10.1037/0022-006X.73.6.1154.PubMedCrossRefGoogle Scholar
  10. 10.
    Hanson RK, Morton-Bourgon KE. The accuracy of recidivism risk assessments for sexual offenders: a metaanalysis of 118 prediction studies. Psychol Assess. 2009;21:1–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Harris AJR, Hanson RK. La récidive sexuelle: d'une simplicité trompeuse. In: civile Spep, editor. Ottawa, Canada2004.Google Scholar
  12. 12.
    Prentky R, Burgess AW. Rehabilitation of child molesters: a cost-benefit analysis. Am J Orthopsychiatry. 1990;60(1):108–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Schmucker M, Losel F. Does sexual offender treatment work? A systematic review of outcome evaluations. Psicothema. 2008;20(1):10–9.PubMedGoogle Scholar
  14. 14.
    McConaghy N. Paedophilia: a review of the evidence. Aust N Z J Psychiatr. 1998;32(2):252–65. discussion 66-7.CrossRefGoogle Scholar
  15. 15.
    Hall RC. A profile of pedophilia: definition, characteristics of offenders, recidivism, treatment outcomes, and forensic issues. Mayo Clin Proc. 2007;82(4):457–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Rosler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med. 1998;338(7):416–22. doi:10.1056/NEJM199802123380702.PubMedCrossRefGoogle Scholar
  17. 17.
    Murray JB. Psychological profile of pedophiles and child molesters. J Psychol. 2000;134(2):211–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry. 2000;57(11):1012–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92(2):111–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Virkkunen M, De Jong J, Bartko J, Goodwin FK, Linnoila M. Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. Arch Gen Psychiatry. 1989;46(7):600–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, et al. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994;51(1):20–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Maes M, van West D, De Vos N, Westenberg H, Van Hunsel F, Hendriks D, et al. Lower baseline plasma cortisol and prolactin together with increased body temperature and higher mCPP-induced cortisol responses in men with pedophilia. Neuropsychopharmacology. 2001;24(1):37–46. doi:10.1016/S0893-133X(00)00177-9.PubMedCrossRefGoogle Scholar
  23. 23.
    Baratta A, Javelot H, Morali A, Halleguen O, Weiner L. The role of antidepressants in treating sex offenders. Sexologies. 2012;21:106–8.CrossRefGoogle Scholar
  24. 24.
    Hill A, Briken P, Kraus C, Strohm K, Berner W. Differential pharmacological treatment of paraphilias and sex offenders. Int J Offender Ther Comp Criminol. 2003;47(4):407–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C. Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.2002 Contract No.: 28.Google Scholar
  26. 26.
    Thibaut F. Pharmacological treatment of sex offenders. Sexologies. 2011;20:166–8.CrossRefGoogle Scholar
  27. 27.
    Fedoroff JP. Antiandrogens vs serotonergic medications in the treatment of sex offenders: a preliminary compliance study. Can J Hum Sex. 1995;4:111–23.Google Scholar
  28. 28.
    Simon NG, Cologer-Clifford A, Lu SF, McKenna SE, Hu S. Testosterone and its metabolites modulate 5HT1A and 5HT1B agonist effects on intermale aggression. Neurosci Biobehav Rev. 1998;23(2):325–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974–84.PubMedGoogle Scholar
  30. 30.
    Wille R, Beier KM. Castration in Germany. Ann Sex Res. 1989;2:103–33.Google Scholar
  31. 31.
    Bradford JM. The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatr. 2001;46(1):26–34.Google Scholar
  32. 32.
    Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther. 2009;31(1):1–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Krueger RB, Hembree W, Hill M. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency. Sex Abuse. 2006;18(2):227–8. doi:10.1007/s11194-006-9012-5.PubMedGoogle Scholar
  34. 34.
    Jeffcoate WJ, Matthews RW, Edwards CR, Field LH, Besser GM. The effect of cyproterone acetate on serum testosterone, LH, FSH and prolactin in male sexual offenders. Clin Endocrinol. 1980;13(2):189–95.CrossRefGoogle Scholar
  35. 35.
    Neuman F. Pharmacology and potential use of cyproterone acetate. Horm Metab Res. 1977;9:1–13.CrossRefGoogle Scholar
  36. 36.
    Codispoti VL. Pharmacology of sexually compulsive behavior. Psychiatr Clin N Am. 2008;31(4):671–9. doi:10.1016/j.psc.2008.06.002.CrossRefGoogle Scholar
  37. 37.
    Meyer JW, Cole CM. Physical and chemical castration of sex offenders. J Off Rehab. 1997;25(3–4):1–18.CrossRefGoogle Scholar
  38. 38.
    Laschet U, Laschet L. Antiandrogens in the treatment of sexual deviations of men. J Steroid Biochem. 1975;6(6):821–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Hansen H, Lykke-Olesen L. Treatment of dangerous sexual offenders in Denmark. J Forensic Psychiatr. 1997;8:195–9.CrossRefGoogle Scholar
  40. 40.
    Czerny JP, Briken P, Berner W. Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry. 2002;17(2):104–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand. 1993;87(6):445–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Thibaut F, Cordier B, Kuhn JM. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment? Psychoneuroendocrinology. 1996;21(4):411–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Thibaut F, Kuhn JM, Cordier B, Petit M. Hormone treatment of sex offenses. Encephale. 1998;24(2):132–7.PubMedGoogle Scholar
  44. 44.
    Schober JM, Kuhn PJ, Kovacs PG, Earle JH, Byrne PM, Fries RA. Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav. 2005;34(6):691–705. doi:10.1007/s10508-005-7929-2.PubMedCrossRefGoogle Scholar
  45. 45.
    Brahams D. Voluntary chemical castration of a mental patient. Lancet. 1988;1(8597):1291–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Ward T, Gannon TA, Birgden A. Human rights and the treatment of sex offenders. Sex Abuse. 2007;19(3):195–216. doi:10.1007/s11194-007-9053-4.PubMedGoogle Scholar
  47. 47.
    Berlin FS. Sex offender treatment and legislation. J Am Acad Psychiatry Law. 2003;31(4):510–3.PubMedGoogle Scholar
  48. 48.
    Silverman WA. The myth of informed consent: in daily practice and in clinical trials. J Med Ethics. 1989;15(1):6–11.PubMedCrossRefGoogle Scholar
  49. 49.
    Belgian Advisory Commitee on Bioethics. Opinion no. 39 of December 18th 2006 on hormonal treatment of sex offender. 2006. In: http://www.health.belgium.be/internet2Prd/groups/public/@public/@dg1/@legalmanagement/documents/ie2divers/18074794.pdf. Accessed 16 Feb 2011.
  50. 50.
    Moulier V, Fonteille V, Pelegrini-Issac M, Cordier B, Baron-Laforet S, Boriasse E, et al. A pilot study of the effects of gonadotropin-releasing hormone agonist therapy on brain activation pattern in a man with pedophilia. Int J Offender Ther Comp Criminol. 2012;56(1):50–60. doi:10.1177/0306624X10392191.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Frederico Duarte Garcia
    • 1
    • 2
  • Heloise Garcia Delavenne
    • 1
  • Alessandra de Fátima Almeida Assumpção
    • 1
  • Florence Thibaut
    • 3
  1. 1.Department of Psychiatry, INCT - de Medicina Molecular, Faculdade de Medicina Universidade Federal de Minas Gerais (UFMG)Belo HorizonteBrazil
  2. 2.Inserm Unit 1073Rouen UniversityRouenFrance
  3. 3.Rouen University HospitalFaculty of Medicine, INSERM U675RouenFrance

Personalised recommendations